文章：

早期可手术切除非小细胞肺癌的新辅助、围手术期及辅助免疫治疗：进展与未来展望

Neoadjuvant, Perioperative, and Adjuvant Immunotherapy in Early-Stage Surgically Resectable Non-Small Cell Lung Cancer: Updates and Future Perspectives

原文发布日期：21 June 2025

DOI: 10.3390/cancers17132077

类型: Article

开放获取: 是

英文摘要：

Historically, systemic therapy for resectable non-small cell lung cancer (NSCLC) has been associated with a modest impact on overall survival. The current treatment options for early-stage resectable NSCLC include neoadjuvant, adjuvant, and perioperative immunotherapy in combination with chemotherapy. In this review, we explore the current treatment paradigms and emerging opportunities for improved survival outcomes from using immunotherapeutic approaches in the treatment of early-stage resectable NSCLC. The incorporation of immunotherapy into neoadjuvant, adjuvant, and perioperative treatment of surgically resectable NSCLC has yielded improved outcomes beyond chemotherapy-alone approaches. Despite this, there remains a margin for improving survival outcomes for patients. Clinical trials utilizing novel agents and approaches that modulate the anti-tumor immune response are currently ongoing and will likely inform the future treatment landscape for early-stage surgically resectable NSCLC.

摘要翻译： 

历史上，可切除非小细胞肺癌（NSCLC）的系统性治疗对总生存期的改善作用较为有限。目前早期可切除NSCLC的治疗方案包括新辅助、辅助及围手术期免疫治疗联合化疗。本综述探讨了当前治疗模式及通过免疫治疗方法改善早期可切除NSCLC生存结局的新兴机遇。将免疫治疗纳入可手术切除NSCLC的新辅助、辅助及围手术期治疗，已取得优于单纯化疗的疗效提升。尽管如此，患者生存结局仍有提升空间。目前正在开展利用新型药物及调控抗肿瘤免疫反应方法的临床试验，这些研究很可能为早期可手术切除NSCLC的未来治疗格局提供重要参考。

原文链接：

Neoadjuvant, Perioperative, and Adjuvant Immunotherapy in Early-Stage Surgically Resectable Non-Small Cell Lung Cancer: Updates and Future Perspectives